Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress
Rhea-AI Summary
Eledon Pharmaceuticals (Nasdaq: ELDN) will present new clinical data on tegoprubart in kidney transplantation at the American Transplant Congress in Boston from June 20-24, 2026.
Presentations include updated Phase 2 BESTOW results, long-term extension data, and a June 22, 2026 investor conference call.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
ELDN gained 5.17% while key biotech peers (e.g., MCRB, NKTX, AARD, CABA, NVCT) were all down between -0.48% and -1.72%, suggesting a stock-specific reaction.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 06 | Islet data update | Positive | +0.7% | Investigator-led islet transplant data showing insulin independence and low HbA1c. |
| Mar 10 | Orphan designation | Positive | +0.0% | FDA Orphan Drug designation for liver transplant allograft rejection prevention. |
| Nov 06 | Phase 2 BESTOW data | Positive | -49.8% | Phase 2 BESTOW kidney transplant results presented at ASN Kidney Week 2025. |
| Jul 17 | Phase 1b update | Positive | -1.3% | Announcement of upcoming Phase 1b kidney transplant presentations at WTC 2025. |
| Sep 04 | BESTOW enrollment | Positive | -5.8% | Early completion of Phase 2 BESTOW enrollment ahead of schedule. |
Clinical-trial headlines have often seen selling pressure: three of five prior clinical updates produced negative 24-hour moves, including a -49.76% reaction to Phase 2 BESTOW data, despite generally constructive clinical narratives.
Over the past two years, Eledon has consistently highlighted progress for tegoprubart in transplantation. Prior clinical updates covered BESTOW enrollment, Phase 1b kidney transplant data, Phase 2 BESTOW readout, and new islet transplant results, plus FDA Orphan Drug designations. These events produced mixed share reactions, with an average move of -11.26% on clinical news, indicating historically cautious trading around data. Today’s announcement continues that BESTOW storyline with new long-term kidney transplant data.
Historical Comparison
Clinical-trial headlines for ELDN have averaged a -11.26% move. Today’s +5.17% gain on new BESTOW long‑term data represents a more favorable reaction than prior trial updates.
Clinical news has progressed from BESTOW enrollment and early Phase 1b kidney data to full Phase 2 BESTOW results. The current article extends this arc with long-term Phase 2 BESTOW extension data in kidney transplantation.
Regulatory & Risk Context
An effective S-3 shelf filed on May 1, 2026 allows Eledon to offer up to $500,000,000 in various securities, including an at-the-market program for up to $75,000,000 of common stock, which provides flexibility for future capital raises.
Market Pulse Summary
This announcement outlines upcoming presentations of updated Phase 2 BESTOW and long-term extension data for tegoprubart in kidney transplantation at the American Transplant Congress. It fits into a long-running clinical narrative where past trial-related headlines averaged a -11.26% move, highlighting sensitivity to data details. Investors may watch the June 2026 presentations and follow-up call closely, alongside the existing $500,000,000 shelf and ATM capacity disclosed in recent filings.
AI-generated analysis. Not financial advice.
Conference call and webcast to discuss results to be held on June 22, 2026 at 8 a.m. ET
IRVINE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that the Company will present new clinical data from its tegoprubart program in patients undergoing kidney transplantation in an oral and a poster presentation at the American Transplant Congress (ATC) taking place in Boston, MA from June 20-24, 2026. Results will include updated data from the Phase 2 BESTOW clinical trial and new long-term data from the Phase 2 BESTOW extension study.
Details on the presentations are below:
Oral Presentation
Title: Phase 2 BESTOW Trial: Evaluating Tegoprubart’s Safety and Efficacy in Preventing Kidney Transplant Rejection
Presenter: Andrew Adams, M.D., Ph.D., Professor of Surgery and Chief Division of Transplantation, John S. Najarian Surgical Chair in Clinical Transplantation, Department of Surgery, University of Minnesota; Executive Medical Director, Solid Organ Transplant Service Line, M Health Fairview
Abstract Publication Number: 585
Session Title: Emerging Discoveries Oral Abstract Session - Kidney: Biomarkers -3
Session Date and Time: Monday, June 22, 2026, from 11:15 a.m. - 12:15 p.m. ET
Session Room: 253BC (Level 2)
Presentation Time: 12:03 p.m. – 12:15 p.m. ET
Poster Presentation
Title: Phase 2 BESTOW Extension Trial Evaluating Tegoprubart’s Long-Term Safety and Efficacy in Preventing Kidney Transplant Rejection
Session Date and Time: Saturday, June 20, 2026, from 5:45 p.m. - 6:45 p.m. ET
Following the conference, a copy of the oral and poster presentation will be available in the Investors section of the Company’s website at https://ir.eledon.com/news-and-events/publications-and-presentations.
Conference Call
Eledon will hold a conference call on June 22, 2026 at 8:00 a.m. Eastern Time to discuss updated data from the Phase 2 BESTOW clinical trial and new long-term data from the Phase 2 BESTOW extension study presented at the American Transplant Congress. The dial-in numbers are 1-800-717-1738 for domestic callers and 1-646-307-1865 for international callers. The conference ID is 84665. A live webcast of the conference call will be available on the Investor Relations section of the Company's website at www.eledon.com. The webcast will be archived on the website following the completion of the call.
About Eledon Pharmaceuticals and tegoprubart
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, islet cell transplantation, liver transplantation and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.
Follow Eledon Pharmaceuticals on social media: LinkedIn; X
Investor Contact:
Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com
Media Contact:
Jenna Urban
CG Life
(212) 253 8881
jurban@cglife.com
Source: Eledon Pharmaceuticals
